Related Experiment Video
Updated: Jun 26, 2025
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Nephroprotective Effects of Mycophenolate Mofetil and Glibenclamide on Streptozotocin-induced Diabetic Renal Injury
Sangeetha Lakshmi Boju1, Peddanna Kotha2, A Nasreen3
1Department of Nephrology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.
Abstract:
Diabetic renal injury is a microvascular complication associated with inflammation and oxidative stress, culminating in renal dysfunction. Conventionally, it is treated with hypoglycemic agents to address metabolic perturbations. However, the way to mitigate immunological, inflammation, and oxidative stress have seldom been studied. Hence, in the present study, the nephroprotective role of immunosuppressive and anti-inflammatory drugs, mycophenolate mofetil (MMF) in combination with the oral hypoglycemic agent glibenclamide, on streptozotocin (STZ)- induced diabetic renal damage was studied. Bodyweight, fasting blood glucose, and glycosylated hemoglobin levels were altered in the diabetic rats. Furthermore, renal injury was indicated by abnormal levels of urinary protein and creatinine and serum markers of renal function in diabetic rats. Hyperglycemia-induced oxidative stress and inflammation were also observed in the diabetic rats. The combination of MMF and glibenclamide treatment significantly attenuated the abnormal effects of hyperglycemia, oxidative stress, and inflammation-induced renal injury in diabetic rats. Histopathological studies confirmed the nephroprotective role of MMF and glibenclamide by reversing renal injury in diabetic rats. The present study suggests that MMF and glibenclamide have a protective role in STZ-induced diabetic renal damage.
Insights
This study investigated the protective effects of mycophenolate mofetil (MMF) and glibenclamide on diabetic kidney damage. The combination therapy effectively reduced hyperglycemia, oxidative stress, and inflammation, preserving renal function in diabetic rats.
Area of Science:
- Nephrology
- Pharmacology
- Diabetology
Background:
- Diabetic renal injury is a microvascular complication driven by inflammation and oxidative stress.
- Current treatments focus on glycemic control, often neglecting the inflammatory and oxidative pathways.
- There is a need for therapeutic strategies that address multiple facets of diabetic kidney disease.
Purpose of the Study:
- To evaluate the nephroprotective effects of combining mycophenolate mofetil (MMF), an immunosuppressive and anti-inflammatory drug, with glibenclamide, an oral hypoglycemic agent.
- To investigate the impact of this combination therapy on streptozotocin (STZ)-induced diabetic renal damage in rats.
- To assess the mitigation of hyperglycemia, oxidative stress, and inflammation-induced renal injury.
Main Methods:
- Induction of diabetes and renal damage in rats using streptozotocin (STZ).
- Administration of a combination therapy of MMF and glibenclamide.
- Assessment of biochemical markers including body weight, fasting blood glucose, glycosylated hemoglobin, urinary protein and creatinine, and serum renal function markers.
- Evaluation of oxidative stress and inflammation markers.
- Histopathological examination of renal tissues.
Main Results:
- STZ-induced diabetic rats exhibited altered body weight, hyperglycemia, elevated glycosylated hemoglobin, and impaired renal function markers.
- Diabetic rats showed increased oxidative stress and inflammation.
- Combination treatment with MMF and glibenclamide significantly attenuated hyperglycemia, oxidative stress, and inflammation.
- The treatment reversed STZ-induced renal injury, as confirmed by histopathological analysis.
Conclusions:
- Mycophenolate mofetil (MMF) in combination with glibenclamide demonstrates significant nephroprotective effects against STZ-induced diabetic renal damage.
- The combination therapy mitigates hyperglycemia, oxidative stress, and inflammation, thereby preserving renal function.
- This therapeutic approach offers a promising strategy for managing diabetic kidney disease by targeting multiple pathological pathways.
